BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

Phase 2 Completed 369 enrolled Braintree Laboratories

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.

Timeline

Start: 2013-02
Primary completion: 2013-11
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BLI1100	Unknown	—	Topical

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

Summary

Timeline

Drugs

Indications